Esther Lu, PhD

Medical School Department Biostatistics
Research Program Prevention and Control
Esther Lu

Researcher Background

Primary Academic Title

Professor of Surgery, Division of Public Health Sciences, WashU Medicine

Education

  • 2001: MS, National University of Singapore
  • 2007: PhD, Medical College of Wisconsin Milwaukee, WI

Research & Selected Publications

Research Interest

Survival data analysis; propensity score approach; study designs in ethical trials; and data analysis.

Research Publications

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.
Authors:

Campian JL, Le SB, Ghiaseddin A, one or more additional authors omitted Liu J, one or more additional authors omitted Tran DD

Journal & Year:

Nat Commun • 2026

Selecting the optimal longitudinal cluster randomized design with a continuous outcome: Parallel-arm, crossover, or stepped-wedge.
Authors:

Liu J, Li F, Sutcliffe S, Colditz GA

Journal & Year:

Stat Methods Med Res • 2025

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
Authors:

Grierson PM, Wolf C, Suresh R, one or more additional authors omitted Liu J, one or more additional authors omitted Lim KH

Journal & Year:

Clin Cancer Res • 2025

Optimal designs using generalized estimating equations in cluster randomized crossover and stepped wedge trials.
Authors:

Liu J, Li F

Journal & Year:

Stat Methods Med Res • 2024

Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
Authors:

Adkins D, Ley JC, Liu J, Oppelt P

Journal & Year:

Lancet Oncol • 2024

A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Authors:

Grierson PM, Suresh R, Tan B, one or more additional authors omitted Liu J, one or more additional authors omitted Lim KH

Journal & Year:

Clin Cancer Res • 2023